ANNETTE MORALES: Open Payments
NPI 1295271831 · BAYONNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 27 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $422 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $180 |
| GlaxoSmithKline, LLC. | 4 | $70 |
| Merck Sharp & Dohme LLC | 4 | $66 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| Lilly USA, LLC | 2 | $36 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Corcept Therapeutics | 1 | $16 |
| Abbott Laboratories | 1 | $16 |
| Gilead Sciences, Inc. | 1 | $16 |
Products named: Wegovy, VERQUVO, TRELEGY ELLIPTA, FARXIGA, JARDIANCE, MOUNJARO, Ozempic, XIFAXAN.
Industry payments across NJ — which companies pay providers there.
